Leaders of Zhang Lei from Anhui Provincial Food and Drug Administration visited Deepblue Medical for research and guidance

Nov 05, 2021

On the afternoon of November 2, 2021, Deputy Director Zhang Lei of Anhui Provincial Drug Administration (hereinafter referred to as "Provincial Drug Administration") and the leaders of the licensing registration office visited Anhui Deepblue Medical for research and guidance. Anhui Deepblue Medical Technology Co., Ltd. (hereinafter (referred to as "Deepblue Medical") Chairman Zhang Chao and General Manager Chen Fengling warmly received and accompanied the whole process, and the principals of various functional departments participated in the meeting.

Leaders of Zhang Lei from Anhui Provincial Food and Drug Administration visited Deep Blue Medical for research and guidance


During the research activities, the leaders of the Provincial Food and Drug Administration made an in-depth on-site inspection, and successively visited the Deepblue medical research and development center, quality inspection center, production workshop, warehouse, etc. Zhang Chao, the chairman of the company, introduced the development history, industrial chain, domestic and foreign development of deepblue medical The layout and product development, etc., and made a report on the company's future development plan. Director Zhang and his party fully affirmed the development of Deepblue Medical for more than ten years.


Leaders of Zhang Lei from Anhui Provincial Food and Drug Administration visited Deep Blue Medical for research and guidance

At the symposium, Deputy Director Zhang analyzed and introduced the draft of Anhui Province's second-class medical device priority approval method, emphasizing that the provincial bureau takes the enterprise service purpose and implements the State Council's policy of delegating, regulating and serving; for common problems in enterprise registration and quality management issues to communicate. Deputy Director Zhang and Director Chen Yongmei and Deputy Director Xiong Yongheng of the Licensing Registration Office expressed that the Provincial Food and Drug Administration is willing to be a bridge between enterprises and the State Food and Drug Administration and other units to help enterprises solve related difficulties in the development process. Regarding the issues of concern in the research and development of enterprises, he said that he would consider establishing an early intervention mechanism in the registration stage to avoid detours in the registration application, and further optimize the medical device review process to speed up the review progress.


Finally, the leaders of the Provincial Food and Drug Administration hope that Deepblue Medical will continue to innovate in research and development, and according to the market transition from "passive health management" to "active health management", strive to produce more products that meet market demand, and truly give full play to POCT products. The role of health warning.


General Manager Chen Fengling said that he thanked the leaders of the provincial bureau for their concern and spared no time to go to the enterprise to provide door-to-door service. Deepblue Medical will give full play to its talents and technical advantages, innovate ideas, fully participate in the construction of the whole industry chain of in vitro diagnostics in Anhui Province, and contribute to the development of the industry.


SEND A MESSAGE
If you have questions or suggestions,please leave us a message,we will reply you as soon as we can!
  • # Address

    Pearl Industrial Park,106 Innovation Avenue, High-Tech Development Zone / No. 777 Jimingshan Road, High-Tech Development Zone, 230088 Hefei, Anhui, PEOPLE'S REPUBLIC OF CHINA

  • # Call Us

    Tel : +86-551-65326797

  • # email us

    Email : sales@dbluemedical.com

top
Leave A Message
Leave A Message
If you have questions or suggestions,please leave us a message,we will reply you as soon as we can!

Home

Product